{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:35Z","timestamp":1790767295199,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Diazoxide is first\u2010line treatment for hyperinsulinaemic hypoglycaemia (HH) but diazoxide\u2010induced pulmonary hypertension (PH) can occur. We aim to characterize the incidence and risk factors of diazoxide\u2010induced PH in a large HH cohort to provide recommendations for anticipating and preventing PH in diazoxide\u2010treated patients with HH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and Patients<\/jats:title><jats:p>Retrospective cohort study involving four UK regional HH centres; review of case notes of HH patients on diazoxide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>The diagnosis of PH was based on clinical and echocardiography evidence. Patient and treatment\u2010related risk factors were analysed for association.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen (6 men) of 177 HH diazoxide\u2010treated patients developed PH, an incidence of 7%. In the PH group, HH was diagnosed at median (range) of 9 (1,180) days, with diazoxide commenced 4 (0,76) days from diagnosis and reaching a maximum dose of 7 (2.5,20) mg\/kg\/d. The majority (8 of 13 patients) developed PH within 2\u00a0weeks of diazoxide. Complete diazoxide withdrawal, but not dose reduction, led to PH resolution at 41 (3,959) days. In three patients, PH continued beyond 12\u00a0months. Risk factors for the development of PH included the presence of congenital heart disease (CHD) (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.008), and total fluid volume exceeding 130\u00a0mL\/kg\/d in the immediate 24\u00a0hours preceding diazoxide (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.019).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pulmonary hypertension can occur in 7% of diazoxide\u2010treated HH patients. Risk factors include the presence of congenital heart disease and fluid overload. Recommendations include echocardiography and fluid restriction to 130\u00a0mL\/kg\/d prior to diazoxide treatment and immediate discontinuation of diazoxide if PH develops.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.14096","type":"journal-article","created":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T13:38:40Z","timestamp":1568468320000},"page":"770-775","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Diazoxide\u2010induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom"],"prefix":"10.1111","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-6360","authenticated-orcid":false,"given":"Suet Ching","family":"Chen","sequence":"first","affiliation":[{"name":"Paediatric Endocrinology Royal Hospital for Children NHS Greater Glasgow and Clyde Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-3136","authenticated-orcid":false,"given":"Antonia","family":"Dastamani","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Great Ormond Street Hospital for Children NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Pintus","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Alder Hey Children's Hospital Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-6479","authenticated-orcid":false,"given":"Daphne","family":"Yau","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Royal Manchester Children's Hospital Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sommayya","family":"Aftab","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Great Ormond Street Hospital for Children NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bath","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Royal Hospital for Sick Children Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Swinburne","sequence":"additional","affiliation":[{"name":"Paediatric Cardiology Royal Hospital for Children NHS Greater Glasgow and Clyde Glasgow Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hunter","sequence":"additional","affiliation":[{"name":"Paediatric Cardiology Royal Hospital for Children NHS Greater Glasgow and Clyde Glasgow Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Giardini","sequence":"additional","affiliation":[{"name":"Paediatric Cardiology Great Ormond Street Hospital for Children NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Christov","sequence":"additional","affiliation":[{"name":"Paediatric Cardiology Great Ormond Street Hospital for Children NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Senniappan","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Alder Hey Children's Hospital Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraneel","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Royal Manchester Children's Hospital Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Guftar","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Royal Hospital for Children NHS Greater Glasgow and Clyde Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Shah","sequence":"additional","affiliation":[{"name":"Paediatric Endocrinology Great Ormond Street Hospital for Children NHS Foundation Trust London UK"},{"name":"Genetics and Genomic Medicine Programme University College London Great Ormond Street Institute of Child Health London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10]]},"reference":[{"issue":"1","key":"e_1_2_7_2_1","first-page":"30","article-title":"The genetics of neonatal hyperinsulinism","volume":"59","author":"Fournet JC","year":"2003","journal-title":"Horm Res"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004310100850"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004310100847"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992288802700307"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.2.408"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.3.476"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00060"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2014.19.2.57"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.1655"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050900"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01613"},{"key":"e_1_2_7_13_1","unstructured":"US Food and Drug Administration.FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide).2015.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safetycommunication-fda-warns-about-serious-lung-condition-infants-and-newborns-treated. Accessed September 23 2019."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-017-1652-3"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000497458"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.09.045"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-008-0049-3"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2007.20.8.939"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2004.01276.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000356772"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201602-110CME"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.11648\/j.ajp.20160201.11"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S198255"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.14096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.14096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cen.14096","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.14096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T22:28:17Z","timestamp":1694212097000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.14096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/cen.14096"],"URL":"https:\/\/doi.org\/10.1111\/cen.14096","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"2019-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}